Osimertinib vs Gefitinib and Erlotinib: — Is the Costlier Drug Worth It?

Tell your oncologist directly. This is a practical problem they deal with regularly, and there are paths forward: the manufacturer runs a patient assistance programme for osimertinib in India, and your team may know of other access routes. If none of these work, a sequencing plan starting with gefitinib or erlotinib — with a clear plan for repeat testing when the cancer progresses — is a legitimate alternative, not a second-rate one. Do not stop treatment or switch drugs without telling your team first.

In many cases, yes. If your cancer progresses on gefitinib or erlotinib and repeat testing finds the T790M resistance mutation, switching to osimertinib is the standard recommendation. The uncertainty is that T790M does not develop in every patient — other resistance mechanisms exist that osimertinib does not address, and those patients will have fewer options at that point. This is one of the main reasons guidelines prefer osimertinib from the start where it is accessible. Discuss the repeat-testing plan with your oncologist before you begin a first-generation drug.

Yes, and it is specifically recommended in this setting. First-generation drugs reach the brain at much lower concentrations, which limits their effectiveness there. Osimertinib crosses the blood-brain barrier at levels that are clinically meaningful, and the FLAURA trial data showed a lower rate of CNS progression with osimertinib than with gefitinib or erlotinib. If brain metastases are present or considered a significant risk, this is one of the clearest reasons your oncologist may favour osimertinib over the earlier generation.

Not necessarily worse overall — different. Osimertinib tends to cause milder skin rash than erlotinib, which is known for prominent skin reactions. Diarrhoea is common with all three. The main additional monitoring required for osimertinib is an ECG before and during treatment, because of a small risk of QT prolongation — a change in the heart's electrical rhythm. This is manageable, but your team will check it regularly. Tell them immediately if you notice palpitations, dizziness, or fainting during treatment.

Generic osimertinib has become available in India following patent decisions. Availability and pricing vary. Discuss this with your oncologist or pharmacist rather than sourcing it independently — dosing and formulation need to match what your team has prescribed, and quality varies between manufacturers. Your treating team is the right place to check what is currently approved and available through legitimate channels in your situation.

Not automatically. EGFR positive means one of these drugs is likely relevant, but which one depends on the specific mutation found. Exon 19 deletion and L858R are sensitive to all three. Some other EGFR mutations — exon 20 insertions, for example — are not well covered by any of these drugs and require different treatment entirely. Your oncologist will match the specific mutation type on your report to the drug most likely to help. If you are unsure which mutation you have, ask for the molecular report in writing — you are entitled to it, and it is worth keeping.